|
Jul 29
|
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
|
|
Jul 23
|
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
|
|
Jul 22
|
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
|
|
Jul 16
|
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
|
|
Jul 10
|
Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
|
|
Jun 30
|
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
|
|
Feb 19
|
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025
|
|
Feb 18
|
Oncolytics Biotech Receives German Clearance for Pancreatic Cancer Study
|
|
Feb 18
|
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
|
|
Feb 14
|
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
|
|
Jan 1
|
Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely?
|
|
Oct 7
|
ONCY Stock Up on Regulatory Update From Breast Cancer Program
|
|
Oct 7
|
Oncolytics targets accelerated approval for oncolytic virus therapy
|
|
Oct 4
|
Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path
|
|
Aug 2
|
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference
|
|
Aug 1
|
Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights
|
|
Jul 24
|
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
|
|
Jun 27
|
Oncolytics Biotech UP 1.9% In US Premarket Announces "Productive" FDA Type C Meeting on Metastatic Breast Cancer Program
|
|
Jun 27
|
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
|
|
Jun 24
|
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
|